Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

VilonvsCrystagen

Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance

Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides

ImmuneImmune

At a Glance

Quick
comparison

Dose Range

Vilon

5–10 mg

Crystagen

1–100 mcg/kg

Frequency

Vilon

Once daily

Crystagen

Once daily

Administration

Vilon

Subcutaneous injection

Crystagen

Subcutaneous injection

Cycle Length

Vilon

12+ weeks

Crystagen

8-12 weeks

Onset Speed

Vilon

Gradual (3-4 weeks)

Crystagen

Gradual (3-4 weeks)

Evidence Level

Vilon

Limited human trials

Crystagen

Limited human trials

Efficacy

Benefit
ratings

Vilon
Crystagen

Anti-aging

Vilon82%
Crystagen82%

Inflammation

Vilon91%
Crystagen0%

Immune

Vilon85%
Crystagen85%

Recovery

Vilon0%
Crystagen88%

Technical Data

Compound
specifications

Vilon

Molecular Formula

C11H21N3O5

Molecular Weight

275.3 g/mol

Half-Life

Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure

CAS Number

45234-02-4

Crystagen

Molecular Formula

C14H21N3O8

Molecular Weight

359.3 g/mol

Half-Life

Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure

CAS Number

Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Protocols

Dosing
tiers

Vilon

starting

200-500 mcg subcutaneously once daily

Once daily

5 days initial assessment

Begin with the conservative research protocol. Reconstitute lyophilized Vilon in bacteriostatic water or physiological saline. Administer subcutaneously, rotating injection sites. This ultra-short dipeptide is rapidly absorbed. Effects are gradual — immune and epigenetic changes build over the treatment course. Monitor for any injection site reactions.

standard

5 mg subcutaneously once daily

Once daily

5-10 days per treatment course

Standard clinical protocol used in Russian bioregulator therapy. Administer subcutaneously once daily for 5-10 consecutive days. Repeat courses every 3-6 months for sustained immune and geroprotective benefits. Can be combined with Epithalon for comprehensive anti-aging or with Vladonix for enhanced immune support. The SIRT1 upregulation and PARP downregulation initiated during treatment persist beyond the active course.

advanced

10 mg subcutaneously once daily

Once daily

10-12 days per course

Extended protocol for individuals with significant immune compromise or advanced age. Used in clinical studies as adjuvant therapy for cancer patients alongside radio/chemotherapy. Often combined with complementary bioregulators: Thymalin for full-spectrum thymic support, Epithalon for pineal/melatonin function, and Cerluten for neuroprotection. Repeat courses every 3-6 months. Medical supervision recommended for advanced protocols.

Crystagen

starting

0.01-1 mcg/kg subcutaneously once daily

Once daily

5 days initial assessment

Conservative protocol based on patent-specified dosing range (0.01-100 μg/kg). Ultra-low doses are effective because Crystagen operates through signal transduction rather than mass-dependent pharmacology. Reconstitute in bacteriostatic water. Administer subcutaneously. Effects are gradual — thymic epithelial rejuvenation and T-cell maturation build over the treatment course.

standard

5-50 mcg/kg subcutaneously once daily

Once daily or 5 consecutive days per month

5-10 days per treatment course

Standard Khavinson protocol. Can be administered as 5-10 consecutive daily injections per course, or as 5 consecutive days monthly for sustained maintenance. The therapeutic window is extremely wide — therapeutic index exceeds 1000x. Repeat courses every 3-6 months. Can be combined with Epithalon for the synergistic thymic-pineal combination that produced 4.1-fold mortality reduction in clinical study.

advanced

50-100 mcg/kg subcutaneously once daily

Once daily or 5 days weekly for extended courses

10-30 days per course or ongoing monthly cycles

Extended protocol for significant immune compromise. Animal longevity studies used 5 days/week for 12+ months with remarkable safety and efficacy. Often combined with Epithalon for comprehensive thymic-pineal anti-aging support. Medical supervision recommended for advanced protocols. The landmark clinical study used annual peptide courses over 6-8 years.

Applications

Best
suited for

Vilon

Immune system restoration in aging individuals with declining thymic function

Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Adjunctive immunomodulatory support during cancer treatment protocols

Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity

Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols for anti-aging and immune support

Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Crystagen

Restoring thymic function and immune competence in aging individuals with immune senescence

Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting immune function during and after illness recovery

Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Vilon

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Digestive changes

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Crystagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Minor digestive changes

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Research Status

Safety
& evidence

Vilon

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.

Contraindications

  • xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid)
  • xPregnancy and breastfeeding — insufficient reproductive safety data
  • xActive autoimmune disease in flare without medical supervision
  • xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Crystagen

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

Contraindications

  • xKnown hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
  • xPregnancy and breastfeeding — insufficient reproductive safety data
  • xActive autoimmune disease in flare without physician supervision
  • xOrgan transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Decision Guide

Which is
right for you?

Choose Vilon if...

  • Immune system restoration in aging individuals with declining thymic function
  • Adjunctive immunomodulatory support during cancer treatment protocols
  • Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
  • Comprehensive Khavinson bioregulator protocols for anti-aging and immune support

Choose Crystagen if...

  • Restoring thymic function and immune competence in aging individuals with immune senescence
  • Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
  • Supporting immune function during and after illness recovery
  • Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence